Ezh2 antibody | knockout validation | Cell Signaling 5246

This is a knockout-validated antibody summary, based on the publications "The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition", as cited below [1], "Ezh2 Ameliorates Osteoarthritis by Activating TNFSF13B" for immunohistochemistry knockout validation (figure 2a) [2], and "EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy" for western blot knockout validation (figure 4e) [3]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Ezh2 antibody | knockout validation | Cell Signaling 5246 figure 1
Figure 1. Verification of elimination of Ezh2 protein detected by western blotting. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: Ezh2

Catalog number: 5246

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to residues surrounding Arg354 of human Ezh2 protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot, immunoprecipitation (IP), immunohistochemistry (paraffin and frozen), immunofluorescence/immunocytochemistry, flow cytometry, chromatin IP and chromatin IP-seq.

Validation Method

Western blot

Sample

Control and Ezh2-KO bone marrow (myeloid progenitor) cells.

References
  1. Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213:1459-77 pubmed publisher
  2. Du X, Chen Y, Zhang Q, Lin J, Yu Y, Pan Z, et al. Ezh2 Ameliorates Osteoarthritis by Activating TNFSF13B. J Bone Miner Res. 2020;35:956-965 pubmed publisher
  3. Bao Y, Oguz G, Lee W, Lee P, Ghosh K, Li J, et al. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy. Nat Commun. 2020;11:5878 pubmed publisher